Oct 14, 2026 Advanced Medical Solutions Group plc (“AMS” or the “Group”) HomeRNS NewsHolding in CompanyHolding(s) in Company @page Section_1 { size: 595.3pt 841.9pt margin-top: 72pt margin-right: 72pt margin-bottom: 72pt margin-left: 72pt…
Oct 14, 2026
Advanced Medical Solutions Group plc
(“AMS” or the “Group”)
HomeRNS NewsHolding in CompanyHolding(s) in Company
@page Section_1 { size: 595.3pt 841.9pt margin-top: 72pt margin-right: 72pt margin-bottom: 72pt margin-left: 72pt -aw-footer-distance: 35.4pt -aw-header-distance: 35.4pt }
.aspose-root div.Section_1 { margin: 72pt; page: Section_1 }
.aspose-root { font-family: “Times New Roman”; font-size: 12pt; max-width: 600.3pt; width: 600.3pt; margin: 1pt auto; position: relative; display: block }
.aspose-root h1, .aspose-root h2, .aspose-root h3, .aspose-root h4, .aspose-root h5, .aspose-root h6, .aspose-root p { margin: 0 }
.aspose-root table { margin-top: 0; margin-bottom: 0 }
.aspose-root h1 { margin-top: 18pt; margin-bottom: 4pt; page-break-inside: avoid; page-break-after: avoid; line-height: 116%; font-family: “Aptos Display”; font-size: 20pt; font-weight: normal; color: rgba(15, 71, 97, 1) }
.aspose-root h2 { margin-top: 8pt; margin-bottom: 4pt; page-break-inside: avoid; page-break-after: avoid; line-height: 116%; font-family: “Aptos Display”; font-size: 16pt; font-weight: normal; color: rgba(15, 71, 97, 1) }
.aspose-root h3 { margin-top: 8pt; margin-bottom: 4pt; page-break-inside: avoid; page-break-after: avoid; line-height: 116%; font-family: Aptos; font-size: 14pt; font-weight: normal; color: rgba(15, 71, 97, 1) }
.aspose-root h4 { margin-top: 4pt; margin-bottom: 2pt; page-break-inside: avoid; page-break-after: avoid; line-height: 116%; font-family: Aptos; font-size: 12pt; font-weight: normal; font-style: italic; color: rgba(15, 71, 97, 1) }
.aspose-root h5 { margin-top: 4pt; margin-bottom: 2pt; page-break-inside: avoid; page-break-after: avoid; line-height: 116%; font-family: Aptos; font-size: 12pt; font-weight: normal; color: rgba(15, 71, 97, 1) }
.aspose-root h6 { margin-top: 2pt; margin-bottom: 0; page-break-inside: avoid; page-break-after: avoid; line-height: 116%; font-family: Aptos; font-size: 12pt; font-weight: normal; font-style: italic; color: rgba(89, 89, 89, 1) }
.aspose-root .Heading7 { margin-top: 2pt; margin-bottom: 0; page-break-inside: avoid; page-break-after: avoid; line-height: 116%; font-family: Aptos; font-size: 12pt; font-weight: normal; font-style: normal; color: rgba(89, 89, 89, 1); -aw-style-name: heading7 }
.aspose-root .Heading8 { margin-bottom: 0; page-break-inside: avoid; page-break-after: avoid; line-height: 116%; font-family: Aptos; font-size: 12pt; font-weight: normal; font-style: italic; color: rgba(39, 39, 39, 1); -aw-style-name: heading8 }
.aspose-root .Heading9 { margin-bottom: 0; page-break-inside: avoid; page-break-after: avoid; line-height: 116%; font-family: Aptos; font-size: 12pt; font-weight: normal; font-style: normal; color: rgba(39, 39, 39, 1); -aw-style-name: heading9 }
.aspose-root .IntenseQuote { margin: 18pt 43.2pt; text-align: center; line-height: 116%; border-top: 0.75pt solid rgba(15, 71, 97, 1); border-bottom: 0.75pt solid rgba(15, 71, 97, 1); padding-top: 10pt; padding-bottom: 10pt; font-family: Aptos; font-size: 12pt; font-style: italic; color: rgba(15, 71, 97, 1); -aw-border-bottom: 0.5pt single #0f4761; -aw-border-top: 0.5pt single #0f4761; -aw-style-name: intense-quote }
.aspose-root .ListParagraph { margin-left: 36pt; margin-bottom: 8pt; line-height: 116%; font-family: Aptos; font-size: 12pt; -aw-style-name: list-paragraph }
.aspose-root .NormalWeb { margin-top: 5pt; margin-bottom: 5pt; line-height: normal; font-family: “Times New Roman”; font-size: 12pt; -aw-style-name: normal-web }
.aspose-root .Quote { margin-top: 8pt; margin-bottom: 8pt; text-align: center; line-height: 116%; font-family: Aptos; font-size: 12pt; font-style: italic; color: rgba(64, 64, 64, 1); -aw-style-name: quote }
.aspose-root .Subtitle { margin-bottom: 8pt; line-height: 116%; font-family: Aptos; font-size: 14pt; letter-spacing: 0.75pt; color: rgba(89, 89, 89, 1); -aw-style-name: subtitle }
.aspose-root .Title { margin-bottom: 4pt; line-height: normal; font-family: “Aptos Display”; font-size: 28pt; letter-spacing: -0.5pt; -aw-style-name: title }
.aspose-root span.Heading1Char { font-family: “Aptos Display”; font-size: 20pt; color: rgba(15, 71, 97, 1) }
.aspose-root span.Heading2Char { font-family: “Aptos Display”; font-size: 16pt; color: rgba(15, 71, 97, 1) }
.aspose-root span.Heading3Char { font-size: 14pt; color: rgba(15, 71, 97, 1) }
.aspose-root span.Heading4Char { font-style: italic; color: rgba(15, 71, 97, 1) }
.aspose-root span.Heading5Char { color: rgba(15, 71, 97, 1) }
.aspose-root span.Heading6Char { font-style: italic; color: rgba(89, 89, 89, 1) }
.aspose-root span.Heading7Char { color: rgba(89, 89, 89, 1) }
.aspose-root span.Heading8Char { font-style: italic; color: rgba(39, 39, 39, 1) }
.aspose-root span.Heading9Char { color: rgba(39, 39, 39, 1) }
.aspose-root span.Hyperlink { text-decoration: underline; color: rgba(0, 0, 255, 1); -aw-style-name: hyperlink }
.aspose-root span.IntenseEmphasis { font-style: italic; color: rgba(15, 71, 97, 1); -aw-style-name: intense-emphasis }
.aspose-root span.IntenseQuoteChar { font-style: italic; color: rgba(15, 71, 97, 1) }
.aspose-root span.IntenseReference { font-weight: bold; font-variant: small-caps; letter-spacing: 0.25pt; color: rgba(15, 71, 97, 1); -aw-style-name: intense-reference }
.aspose-root span.QuoteChar { font-style: italic; color: rgba(64, 64, 64, 1) }
.aspose-root span.SubtitleChar { font-size: 14pt; letter-spacing: 0.75pt; color: rgba(89, 89, 89, 1) }
.aspose-root span.TitleChar { font-family: “Aptos Display”; font-size: 28pt; letter-spacing: -0.5pt }
.aspose-root .rn-1 { font-family: Verdana }
.aspose-root .rn-2 { font-size: 11pt; background-color: rgba(124, 23, 58, 1) }
.aspose-root .rn-3 { font-family: Verdana; font-weight: bold; color: rgba(255, 255, 255, 1) }
.aspose-root .rn-4 { font-size: 11pt }
.aspose-root .rn-5 { font-family: Verdana; font-weight: bold }
.aspose-root .rn-6 { -aw-import: ignore }
.aspose-root .rn-7 { font-size: 7.5pt }
.aspose-root .rn-8 { border-right: 0.75pt solid rgba(102, 102, 102, 1); border-left: 0.75pt solid rgba(102, 102, 102, 1); border-bottom: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt 0.75pt 5.62pt; vertical-align: middle; background-color: rgba(144, 144, 144, 1) }
.aspose-root .rn-9 { border-left: 0.75pt solid rgba(102, 102, 102, 1); border-bottom: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt 0.75pt 5.62pt; vertical-align: middle; background-color: rgba(144, 144, 144, 1) }
.aspose-root .rn-10 { border-top: 0.75pt solid rgba(102, 102, 102, 1); border-right: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt; vertical-align: middle }
.aspose-root .rn-11 { margin-top: 3.75pt; margin-left: 9.75pt; margin-bottom: 7.5pt; font-size: 11pt }
.aspose-root .rn-12 { border-top: 0.75pt solid rgba(102, 102, 102, 1); border-right: 0.75pt solid rgba(102, 102, 102, 1); border-left: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt; vertical-align: middle }
.aspose-root .rn-13 { font-family: Verdana; -aw-import: ignore }
.aspose-root .rn-14 { border-top: 0.75pt solid rgba(102, 102, 102, 1); border-left: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt; vertical-align: middle }
.aspose-root .rn-15 { font-size: 10pt }
.aspose-root .rn-16 { background-color: rgba(124, 23, 58, 1) }
.aspose-root .rn-17 { font-weight: bold; color: rgba(255, 255, 255, 1) }
.aspose-root .rn-18 { width: 90%; border: 0.75pt solid rgba(102, 102, 102, 1); border-collapse: collapse }
.aspose-root .rn-19 { border: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt; vertical-align: middle }
.aspose-root .rn-20 { border-top: 0.75pt solid rgba(102, 102, 102, 1); border-left: 0.75pt solid rgba(102, 102, 102, 1); border-bottom: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt; vertical-align: middle }
.aspose-root .rn-21 { width: 20%; border-right: 0.75pt solid rgba(102, 102, 102, 1); border-bottom: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt 0.75pt 1.12pt; vertical-align: middle; background-color: rgba(144, 144, 144, 1) }
.aspose-root .rn-22 { border-right: 0.75pt solid rgba(102, 102, 102, 1); border-left: 0.75pt solid rgba(102, 102, 102, 1); border-bottom: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt 0.75pt 1.12pt; vertical-align: middle; background-color: rgba(144, 144, 144, 1) }
.aspose-root .rn-23 { border-left: 0.75pt solid rgba(102, 102, 102, 1); border-bottom: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt 0.75pt 1.12pt; vertical-align: middle; background-color: rgba(144, 144, 144, 1) }
.aspose-root .rn-24 { width: 20%; border-top: 0.75pt solid rgba(102, 102, 102, 1); border-right: 0.75pt solid rgba(102, 102, 102, 1); border-bottom: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt; vertical-align: middle }
.aspose-root .rn-25 { border-top: 0.75pt solid rgba(102, 102, 102, 1); border-right: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt 0.75pt 1.12pt; vertical-align: middle; background-color: rgba(233, 234, 236, 1) }
.aspose-root .rn-26 { border-top: 0.75pt solid rgba(102, 102, 102, 1); border-right: 0.75pt solid rgba(102, 102, 102, 1); border-left: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt; vertical-align: middle; background-color: rgba(233, 234, 236, 1) }
.aspose-root .rn-27 { border-top: 0.75pt solid rgba(102, 102, 102, 1); border-left: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt; vertical-align: middle; background-color: rgba(233, 234, 236, 1) }
.aspose-root .rn-28 { width: 15%; border-top: 0.75pt solid rgba(102, 102, 102, 1); border-right: 0.75pt solid rgba(102, 102, 102, 1); border-bottom: 0.75pt solid rgba(102, 102, 102, 1); padding: 0.75pt 0.38pt; vertical-align: middle }
.aspose-root .rn-29 { margin-top: 3.75pt; margin-left: 3.75pt; margin-bottom: 7.5pt; font-size: 11pt }

RNS Number : 9630Y
Advanced Medical Solutions Grp PLC
14 October 2026
TR-1: Standard form for notification of major holdings
- Issuer Details
ISIN
GB0004536594
Issuer Name
ADVANCED MEDICAL SOLUTIONS GROUP PLC
UK or Non-UK Issuer
UK
- Reason for Notification
An acquisition or disposal of voting rights
- Details of person subject to the notification obligation
Name
JPMorgan Chase & Co.
City of registered office (if applicable)
Country of registered office (if applicable)
US
- Details of the shareholder
| Name | City of registered office | Country of registered office |
| J.P. Morgan Securities PLC | | |
- Date on which the threshold was crossed or reached
09-Oct-2026
- Date on which Issuer notified
13-Oct-2026
- Total positions of person(s) subject to the notification obligation
| | % of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer |
| Resulting situation on the date on which threshold was crossed or reached | 4.324922 | 0.920616 | 5.245538 | 11519416 |
| Position of previous notification (if applicable) | Below minimum threshold | Below minimum threshold | Below minimum threshold | |
- Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
| Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
| GB0004536594 | | 9497710 | | 4.324922 |
| Sub Total 8.A | 9497710 | 4.324922% |
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
| Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
| | | | | |
| Sub Total 8.B1 | | | |
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
| Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
| Cash-settled Equity Swap | 15/10/2026 | 15/10/2026 | Cash | 29991 | 0.013657 |
| Cash-settled Equity Swap | 03/11/2026 | 03/11/2026 | Cash | 10074 | 0.004587 |
| Cash-settled Equity Swap | 27/11/2026 | 27/11/2026 | Cash | 8943 | 0.004072 |
| Cash-settled Equity Swap | 02/12/2026 | 02/12/2026 | Cash | 20308 | 0.009248 |
| Cash-settled Equity Swap | 05/01/2027 | 05/01/2027 | Cash | 264578 | 0.120479 |
| Cash-settled Equity Swap | 15/02/2027 | 15/02/2027 | Cash | 6930 | 0.003156 |
| Cash-settled Equity Swap | 02/03/2027 | 02/03/2027 | Cash | 36831 | 0.016772 |
| Cash-settled Equity Swap | 20/04/2027 | 20/04/2027 | Cash | 11340 | 0.005164 |
| Cash-settled Equity Swap | 19/05/2027 | 19/05/2027 | Cash | 1092000 | 0.497258 |
| Cash-settled Equity Swap | 27/05/2027 | 27/05/2027 | Cash | 147087 | 0.066978 |
| Cash-settled Equity Swap | 14/06/2027 | 14/06/2027 | Cash | 17965 | 0.008181 |
| Cash-settled Equity Swap | 02/07/2027 | 02/07/2027 | Cash | 35336 | 0.016091 |
| Cash-settled Equity Swap | 05/07/2027 | 05/07/2027 | Cash | 313730 | 0.142862 |
| Cash-settled Equity Swap | 03/08/2027 | 03/08/2027 | Cash | 2426 | 0.001105 |
| Cash-settled Equity Swap | 23/08/2027 | 23/08/2027 | Cash | 499 | 0.000227 |
| Cash-settled Equity Swap | 25/08/2027 | 25/08/2027 | Cash | 6008 | 0.002736 |
| Cash-settled Equity Swap | 02/11/2027 | 02/11/2027 | Cash | 3980 | 0.001812 |
| Cash-settled Equity Swap | 02/12/2027 | 02/12/2027 | Cash | 1253 | 0.000571 |
| Cash-settled Equity Swap | 04/10/2027 | 04/10/2027 | Cash | 4211 | 0.001918 |
| Cash-settled Equity Swap | 15/11/2027 | 15/11/2027 | Cash | 6284 | 0.002862 |
| Cash-settled Equity Swap | 24/11/2027 | 24/11/2027 | Cash | 1932 | 0.000880 |
| Sub Total 8.B2 | | 2021706 | 0.920616% |
-
Information in relation to the person subject to the notification obligation
-
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
| Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
| JPMorgan Chase & Co. | J.P. Morgan Securities PLC | 3.598479 | | 4.519095% |
| JPMorgan Chase & Co. | J.P. Morgan SE | | | |
- In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
If date does not apply, explain below
- Additional Information
Chain of controlled undertakings:
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Securities PLC (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan SE (100%)
- Date of Completion
13-Oct-2026
- Place Of Completion
London
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLUSRRRNSURAAA
For further information, please contact:
Advanced Medical Solutions Group plc
Tel: 44 (0) 1606 545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations
Consilium Strategic Communications
Tel: 44 (0) 20 3709 5700
Matthew Neal / Lucy Featherstone
Investec Bank PLC (NOMAD & Broker)
Tel: 44 (0) 20 7597 5970
Gary Clarence / David Anderson
HSBC Bank PLC (Broker)
Tel: 44 (0) 20 7991 8888
Sam McLennan / Joe Weaving / Stephanie Cornish
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.